Incyte Corp. (NASDAQ:INCY) EVP Reid M. Huber sold 2,715 shares of Incyte Corp. stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $109.95, for a total value of $298,514.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Incyte Corp. (NASDAQ:INCY) opened at 104.89 on Tuesday. The firm has a market capitalization of $19.76 billion, a price-to-earnings ratio of 140.98 and a beta of 0.79. The stock’s 50 day moving average price is $91.79 and its 200-day moving average price is $84.00. Incyte Corp. has a 12 month low of $55.00 and a 12 month high of $118.49.

Insider Buying and Selling by Quarter for Incyte Corp. (NASDAQ:INCY)

Several institutional investors have recently made changes to their positions in the stock. Fuller & Thaler Asset Management Inc. purchased a new position in shares of Incyte Corp. during the second quarter valued at approximately $104,000. Acrospire Investment Management LLC raised its position in Incyte Corp. by 18.2% in the second quarter. Acrospire Investment Management LLC now owns 1,300 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 200 shares during the last quarter. Toronto Dominion Bank raised its position in Incyte Corp. by 57.3% in the third quarter. Toronto Dominion Bank now owns 1,457 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 531 shares during the last quarter. Walleye Trading LLC bought a new position in Incyte Corp. during the second quarter valued at about $120,000. Finally, Seven Eight Capital LLC bought a new position in Incyte Corp. during the first quarter valued at about $113,000. Hedge funds and other institutional investors own 92.14% of the company’s stock.

A number of research analysts have issued reports on INCY shares. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Incyte Corp. in a research report on Wednesday, September 28th. SunTrust Banks Inc. assumed coverage on Incyte Corp. in a report on Friday, August 5th. They set a “buy” rating and a $105.00 price target on the stock. Piper Jaffray Cos. restated a “buy” rating and set a $102.00 price target (up from $76.00) on shares of Incyte Corp. in a report on Monday, August 1st. Zacks Investment Research upgraded Incyte Corp. from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a report on Tuesday, July 19th. Finally, Leerink Swann restated a “buy” rating on shares of Incyte Corp. in a report on Monday, July 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twenty-one have given a buy rating to the stock. Incyte Corp. presently has an average rating of “Buy” and an average price target of $104.98.

Incyte Corp. Company Profile

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

5 Day Chart for NASDAQ:INCY

Receive News & Stock Ratings for Incyte Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corp. and related stocks with our FREE daily email newsletter.